Nephros Inc. (NEPH) exhibits 61.9% gross margins and 18.9% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 26.3x enterprise multiple and 4.8% implied options volatility.
Sustained 61.9% gross profitability converts into 6.1% operating margin and 18.9% ROIC, outpacing sector cost of capital.
ROIC: 18.9% // GM: 61.9%YoY revenue trajectory of +32.7% paired with 4.50% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +32.7% // FCF YLD: 4.50%Altman Z-Score of 3.80 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.80 // F-SCORE: 8/9Trading at 29.8x trailing P/E (25.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 29.8x // EV/EBITDA: 26.3xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $3.27 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend 6.4% net margins.
NET MARGIN: 6.4% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for NEPH & activate live FRED threshold breach alerts.